SINGAPORE, Jan. 21, 2026 /PRNewswire/ — Infineum, a global leader in specialty chemicals for lubricants and fuels, has signed a strategic framework agreement with Rianlon Corporation, a specialty chemicals manufacturer based in Tianjin, China. This partnership brings together Infineum’s global formulation and market expertise with Rianlon’s strength in component manufacturing and regional supply capability.

The agreement was signed the day after Rianlon celebrated the groundbreaking of its new component development and manufacturing facility in Johor, Malaysia, underscoring the strategic intent and momentum behind the collaboration.

This partnership represents a timely and customer‑focused response to today’s increasingly complex global trade and geopolitical environment. The collaboration significantly strengthens regional supply resilience, logistics efficiency, and cost competitiveness for customers across China and the wider Asia‑Pacific region.

Chris Locke, Sustainable Transportation EVP of Infineum said, “With this pioneering move, our vision is to ensure that customers can receive the best of both companies’ strengths; Infineum quality products supported by our international footprint and capabilities, leveraging Rianlon’s regional cost efficiency, speed and operational excellence in the manufacture of lubricant additive components.  This is designed to help our customers deliver the high-quality products the market demands while also recognizing the need and focus for cost efficiency, through integrating Rianlon’s regional supply capability into Infineum’s global supply network.”

Henry Li, Chairman of Rianlon Corporation stated, “We believe that by implementing this agreement, we are collaborating with a world-class player, both contributing our distinct and synergistic values. Over the past years, Rianlon has achieved significant technological advancements, particularly in full-category component coverage and differentiated product development, which gives us distinct advantages in multiple related application fields. These include our ability to expedite future technology development, optimize capacity construction costs, and maintain low operating costs in production management and operations. This collaboration agreement is not only significant for Rianlon and Infineum but also, I believe, for helping to create a new industry model towards building a healthy and sustainable lubricants industry in China as a whole.”

Aldo Govi, CEO of Infineum added, “Signing this strategic partnership with Rianlon is a hugely important step for Infineum, with a real focus on creating a regional self-sufficient additive supply chain as part of our global supply network strategy. Rianlon has proven to have superb technical and manufacturing capabilities within China with plans to expand across the Asia Pacific region, which is the perfect match for Infineum and will help both companies to become even more agile and successful amidst the fast-evolving market environment.”

About Infineum

Infineum is a specialty chemicals company that exists to create a sustainable future through innovative chemistry. We focus on complex formulation challenges, working hand in hand with our customers, to deliver mutually successful solutions.

Our heritage is within the energy transition segment, where we have reduced the carbon impact of internal combustion engines, supported electrification, and are developing solutions for alternative fuels.

By taking a forward-looking approach to innovation across multiple sectors, we also maximise the value of Infineum’s unique technology in carbon resilient sectors.

More than 2,000 global employees with unique perspectives and expertise help to contribute to customer success, as we formulate tomorrow together. For more information, visit www.infineum.com.

HONG KONG, Jan. 21, 2026 /PRNewswire/ — Tam Jai International Co. Limited (“TJI” or the “Company“, together with its subsidiaries, the “Group“), one of the leading and renowned restaurant groups in Hong Kong, granted over HK$1.6 million in scholarships to a record number of 49 students this year as the “TJl Education Support Scheme for Employees’ Children” (the “Scheme”) marks its 10-year milestone. Through its year-long “GAME Changer” programme—providing Grant, Advice, Mentorship, and Experience—the Scheme has continued to empower the next generation of talent with comprehensive support, championing the Group’s “Uplifting People” philosophy.

Since its inception in 2015, the Scheme has awarded a total of nearly HK$9 million in scholarship funds to support the undergraduate education of more than 270 children of the Group’s employees, covering up to 80% of their tuition fees at local universities each year. In addition to financial assistance, various CSR activities under the Scheme have benefited over 530 people in need, with 2,830 volunteering hours contributed in the past two years.

Launched in 2024, the “GAME Changer” programme provides comprehensive support for the holistic development of employees’ children, equipping them with essential skills and hands-on experiences to help them transition smoothly into the workplace. TJI staff from various divisions stepped up as mentors, offering full-year guidance and support in students’ individual development journeys; senior management of the Group was paired with students for one-to-one advisory sessions to provide high-level career insights, advising them on different pathway choices. A workshop was also held to equip final-year students with practical job application skills, alongside personality assessment to identify individual strengths and weaknesses, and formal reference letters to facilitate their job searches.

The “Experience” pillar of the programme was realised through CSR activities that deepened students’ community engagement and social awareness, including social services with the Hong Kong Christian Service where students and mentors designed and led interactive activities with newly arrived children to visit elderly people living alone, and collaboration with the Evangelical Lutheran Church of Hong Kong to provide career and life planning activities for more than 170 secondary school students.

As a long-standing highlight of the Scheme, the awardees were also offered a 72-hour internship at the Group’s restaurants to experience their parents’ work, strengthening mutual understanding and parental bonding.

Mr Daren Lau, Chairman and Chief Executive Officer of TJI, said, “I am immensely proud to witness the transformation of the ‘TJI Education Support Scheme for Employees’ Children’ over the past decade. The Scheme has evolved into a more comprehensive initiative, offering not only educational grants but also career guidance, volunteering experiences and internship placement to foster the holistic growth of our employees’ children. This reflects our commitment to uplifting young people and creating shared value for our workforce. As we look ahead, we remain dedicated to deepening our positive impact on the lives of our employees, their families and the community.”

Mentee Sally shared, “As a student majoring in a relatively new field like Data Science, I often felt uncertain about my future career prospects. I am glad to have connected with TJI’s Group Chief Marketing Officer, Mr Ronald Wong, through the programme’s career advisor sessions. Since his expertise is directly related to my major, he provided me with real-world industry insights and valuable career guidance.”

Mentee Claudia said, “I am grateful for the opportunity to take part in the 72-hour internship in TamJai SamGor restaurant. The workplace is vastly different from the classroom, which significantly enhanced my adaptability and interpersonal skills. It also gave me a deeper appreciation of my mom’s dedication to her work and inspired me to take better care of her at home.”

Mentee Macy said, “Before joining the ‘GAME Changer’ programme, I was shy and passive. Thanks to the guidance of my mentor, Heidi, I learned that stepping out of my comfort zone is more important than being perfect. It was rewarding to see the smiles of those we served during our volunteer work, making me realise that even small contributions can make a positive impact.”

About Tam Jai International Co. Limited
As one of the leading restaurant groups in Hong Kong, TJI has rapidly expanded its network to over 240 stores across various markets, including Mainland China, Singapore, Japan, Australia and Malaysia, with plans to enter the Philippines. Apart from self-operating restaurants, the Group also adopts alternative models such as joint venture, franchise or strategic partnership for overseas markets. The Group’s portfolio of distinguished brands includes TamJai Yunnan Mixian (譚仔雲南米線), TamJai SamGor Mixian (譚仔三哥米線), and international brand TamJai Mixian, as well as Japanese dining brands, Marugame Seimen and Yakiniku Yamagyu, through franchise and licensing in Hong Kong.

With highly standardised operations, an innovative spirit and an efficient management model, TJI is committed to providing customers with a quality yet affordable dining experience while ambitiously expanding its footprints across the globe.

For Press Enquiries
Strategic Financial Relations Limited

The Top 100 organizations lead the way in innovation, contributing an exceptional 16% of the world’s highest-strength AI inventions 

LONDON, Jan. 21, 2026 /PRNewswire/ — Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced the 15^th edition of its Top 100 Global Innovators. This annual benchmark celebrates the organizations that consistently deliver high-impact inventions, shaping the future of innovation across industries. The 2026 report reveals how innovation leadership is shifting from scale to precision, and how artificial intelligence (AI) is accelerating this transformation.

The Top 100 Global Innovators navigate complexity with clarity and set the pace for invention quality, originality and global reach. These organizations account for a disproportionate share of the world’s most valuable ideas, demonstrating that innovation leadership is defined by precision and strategic intent. This year’s ranking not only celebrates enduring innovation leadership, but it also reveals the forces reshaping that leadership, with AI at the forefront.

Maroun S. Mourad, President, Intellectual Property, Clarivate, said: “Recognition as a Top 100 Global Innovator is a remarkable achievement given the pace of change and in the 2026 edition, we feature 16 all-time recipient organizations. Multi-year winners and new entrants are investing in AI innovation as it redefines the boundaries between research, engineering and commercial execution. The leaders we celebrate today are not just responding to this shift, they are designing for it.”

AI is no longer a side story; it has become part of the fabric of innovation. The Top 100 Global Innovators 2026 analysis shows that AI-related patent activity has surged dramatically in recent years, with filings doubling repeatedly since 2019 and more than one million invention specifications published by mid-2025. Generative AI and deep learning have grown at an extraordinary pace, making them the fastest-moving frontiers in technology. Within this landscape, the Top 100 Global Innovators account for 16% of the world’s strongest AI inventions, underscoring that leadership today is about quality and strategic clarity, not just volume.

Japan continues to lead the global innovation landscape, with 32 organizations named. It also holds five of the top 10 ranked positions, followed by Mainland China and South Korea, each with two and the United States with one. Following Japan, the United States, with 18 organizations, Taiwan region, with 12, and Germany and South Korea, both with eight, remain the largest contributors overall. Countries/regions showing growth in organizations listed include Mainland China, and the Netherlands, while Ireland and Saudi Arabia return to the list this year.

Other key findings from the 2026 report include:

• Samsung Electronics retains its position as the #1 ranked global innovator.
• Six companies awarded Top 100 status for the first time: Aptiv, CXMT, GE Vernova, Silicon Motion, Subaru and ZTE.
• Six companies re-enter the Top 100: Apple, KLA, LG Display, Saudi Aramco, Signify and TCL Technology.
• 16 all-time recipient organizations retained Top 100 Global Innovator status: Boeing, Dow, Ericsson, Fujitsu, Hitachi, Honda, Honeywell, LG Electronics, NEC, Panasonic, Qualcomm, Samsung Electronics, Shin-Etsu Chemical, Sony, Toshiba, and Toyota.

The Top 100 Global Innovators analysis is underpinned by the Clarivate Center for IP and Innovation Research. Their analyses are founded in rigorous research leveraging the proprietary Derwent Strength Index, derived from the Derwent World Patents Index (DWPI) and its global invention data to measure the influence of ideas, their success and rarity, and the investment in inventions.

To learn more, please visit our Top 100 Global Innovators 2026 site.

Detailed Methodology
The Top 100 Global Innovators uses a complete comparative analysis of global invention data to assess the strength of every patented idea, using measures tied directly to their innovative power. To move from the individual strength of inventions to identifying the organizations that create them more consistently and frequently, Clarivate sets two threshold criteria that potential candidates must meet and then adds a measure of their internationally patented innovation output over the past five years.

For full information, please visit our Top 100 Global Innovators 2026 methodology site.

About Clarivate Center for IP and Innovation Research
The Clarivate Center for IP and Innovation Research empowers organizations worldwide to excel by providing expert guidance grounded in pioneering benchmarks and data-driven insights. Bringing together senior practitioners, consultants and data analysts, the Center performs research to establish and disseminate benchmarks that guide management and strategy. It works with legal, IP and innovation leaders to optimize IP operations and technology and improve IP decision-making, supported by industry-leading data, analytics and proven practices.

About Clarivate
Clarivate is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and expert services in the areas of Academia & Government, Intellectual Property and Life Sciences & Healthcare. For more information, please visit www.clarivate.com

Media contact:
Sofia Nogués, Sr. External Communications Manager
newsroom@clarivate.com 

HONG KONG, Jan. 21, 2026 /PRNewswire/ — Prof Li Liangliang, Associate Professor of the Wu Jieh Yee School of Interdisciplinary Studies (WJYSIS) at Lingnan University, has been elected a Fellow of the Royal Society of Chemistry (FRSC) in recognition of his outstanding contributions to the research and development of new materials chemistry. This honour highlights WJYSIS’s academic influence and value in promoting sustainable development through interdisciplinary innovation and real-world impact.

Prof Li said, “I am deeply honoured to be elected as a Fellow of the Royal Society of Chemistry. This recognition not only affirms my research work, but is also made possible by the excellent research environment provided by Lingnan University, which allows me to collaborate with scholars worldwide, exchange cutting-edge findings, and further advance Lingnan University’s international research presence. I am currently leading the establishment of the Laboratory for Advanced Energy Materials at Lingnan University, and focusing on developing advanced energy materials. We hope to address global energy storage challenges in the future, and contribute more groundbreaking solutions to society.”

Long active in energy materials and battery research, with a particular focus on the discovery and development of all-solid-state batteries and inorganic and polymer solid electrolytes, Prof Li has published over a hundred papers in leading journals such as Advanced Materials, Advanced Energy Materials, Energy Storage Materials, Nano Energy, and Acta Materialia, and holds eight granted invention patents. His accolades include the IEEE Electronics Packaging Society Outstanding Young Engineer Award, and the Second Prize of the Beijing Higher Education Teaching Achievement Award. He currently serves as a Young Editorial Board Member of Rare Metals and Chinese Chemical Letters and is an IEEE Senior Member.

Prof Li and his team have published a pioneering study in top-tier, peer-reviewed, scientific journal Advanced Energy Materials, introducing a new anode-free sodium battery that, by tuning the salt concentration in the electrolyte, reduces the risks of short circuits and shortened lifespan during fast charging. Laboratory tests have demonstrated that this new battery can be charged within minutes while maintaining safety and stability.

Founded in 1841, the Royal Society of Chemistry (RSC) is one of the world’s most prestigious and influential scientific societies. Each year, it confers fellowships on scientists who have made outstanding contributions to the advancement of chemical science.

• Recorded Q4’25 revenue of KRW 1,286 billion and FY’25 revenue of KRW 4,557 billion
• Maintained momentum through consistent operational performance and robust client demand
• Strengthened foundation for long-term growth through expanded manufacturing readiness and operational scale

INCHEON, South Korea, Jan. 20, 2026 /PRNewswire/ — Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), reported financial results for the fourth quarter and fiscal year 2025.

“In 2025, Samsung Biologics delivered stable and resilient performance despite a highly uncertain global environment, supported by disciplined execution and strong demand,” said John Rim, President and CEO of Samsung Biologics. “Consistent operations across our existing plants and successful ramp-up of Plant 4 supported reliable delivery for client programs throughout the year. As we move forward, our planned expansion of manufacturing capabilities, including the addition of a U.S. manufacturing footprint, will further enhance supply chain resilience and responsiveness to global client needs. We remain focused on strengthening manufacturing readiness, operational consistency, and quality excellence to support sustainable long-term growth as a trusted partner to the global biopharmaceutical industry.”

Financial Highlights

In the fourth quarter of 2025, Samsung Biologics reported revenue of KRW 1,286 billion, while operating profit reached KRW 528 billion. The performance was mainly driven by full utilization across Plants 1 through 3, together with Plant 4, which also reached full utilization in the third quarter of 2025.

For the full fiscal year 2025, Samsung Biologics achieved revenue of KRW 4,557 billion, reflecting stable operations and expanded project execution across the company’s manufacturing network.

[Consolidated earnings for CDMO business, post spin-off basis, KRW billion]

Business Updates and 2026 Outlook

Samsung Biologics continued to expand its global CDMO business through long-term partnerships with pharmaceutical companies worldwide. The company secured a KRW 1.1 trillion manufacturing agreement with a European pharmaceutical company in the fourth quarter of 2025, contributing to a cumulative contract value exceeding USD 21 billion. Cumulative regulatory approvals reached 420, reflecting the company’s continued focus on quality, compliance, and consistent regulatory execution across global markets.

The company reaffirmed its strategic direction as a pure-play CDMO through an equity spin-off, and continued to advance initiatives to strengthen its global manufacturing platform. Operations across Plants 1 through 4 remained stable, providing a solid operational base, while Plant 5 will begin contributing to revenue in 2026. Based on this outlook, excluding potential contributions from the planned acquisition of the U.S. site, the company projected 15–20% annual revenue growth for 2026.

Samsung Biologics progressed key infrastructure and capacity investments to support future demand. In December 2025, the company announced the planned acquisition of a U.S. manufacturing facility in Rockville, Maryland, to further support supply resilience and proximity to clients. The site comprises two CGMP manufacturing plants with a combined 60 kL of drug substance capacity, supporting mid- to large-scale programs. The deal is expected to close in the first quarter of 2026, and the company intends to make additional investments to increase capacity and upgrade technology at the site.

The company also secured land for Bio Campus III, establishing a foundation for future expansion to support next-generation modalities and diversified client needs. Bio Campus III is expected to support expanded capabilities across advanced conjugation technologies, as well as cell and gene therapies and antibody vaccines.

Under its optimized manufacturing framework, ExellenS™, Samsung Biologics continued to invest in operational systems, digital capabilities, and manufacturing infrastructure to enhance readiness and execution across its facilities. The company is expanding its drug product capabilities, including preparations for a fully automated pre-filled syringe drug product line, which is expected to be CGMP ready by 2027.

Samsung Biologics continued to advance its environmental, social, and governance (ESG) initiatives. The company received an ‘A’ rating in Water Security from the Carbon Disclosure Project (CDP) and continued its role as a Champion of the Sustainable Markets Initiative, supporting collaborative action toward more sustainable healthcare manufacturing practices. By strengthening engagement with suppliers and integrating ESG considerations across its operations and value chain, Samsung Biologics aims to support long-term environmental stewardship while maintaining reliable and responsible manufacturing operations.

For more details on performance and financials, please refer to the Earnings Release.

About Samsung Biologics Co., Ltd.

Samsung Biologics (KRX: 207940.KS) is a leading contract development and manufacturing organization (CDMO), offering end-to-end integrated services that range from late discovery to commercial manufacturing.

With a combined biomanufacturing capacity of 785,000 liters across Bio Campus I and II, and 60,000 from the planned acquisition of a manufacturing facility in Rockville, Maryland, U.S. upon deal closure at the end of Q1 2026, Samsung Biologics leverages cutting-edge technologies and expertise to advance diverse modalities, including multispecific antibodies, fusion proteins, antibody-drug conjugates, and mRNA therapeutics.

By implementing the ExellenS™ framework across its manufacturing network with standardized designs, unified processes, and advanced digitalization, Samsung Biologics ensures plant equivalency and speed for manufacturing continuity.

Samsung Biologics’ global manufacturing and commercial network spans Korea, the U.S., and Japan. Samsung Biologics America supports clients based in the U.S. and Europe, while its Tokyo sales office serves the APAC region. Samsung Biologics continues to invest in new capabilities to maximize operational and quality excellence, ensuring flexibility and agility for clients. The company is committed to the on-time, in-full delivery of safe, high-quality biomedicines, as well as to making sustainable business decisions for the betterment of society and global health.

For more information, visit https://samsungbiologics.com/.

Media Contact
Claire Kim, Senior Director cair.kim@samsung.com
Becky Lee, Director brite.lee@samsung.com